Journal of Human Hypertension | 2019

Effect of intensive lowering of systolic blood pressure treatment on heart failure events: a meta-analysis of randomized controlled studies

 
 
 
 
 
 
 
 

Abstract


We performed this meta-analysis to assess the association between intensive systolic blood pressure (SBP)-lowering strategies and heart failure (HF). A comprehensive literature review was conducted using English and Chinese databases from their origination through April 2018. Random-effects models were used to calculate pooled relative risks and 95% confidence intervals. Nine randomized controlled trials including a total of 39,936 hypertensive patients were ultimately included in our meta-analysis. Pooled analysis of these nine trials showed that a treatment target of SBP ≤140\u2009mmHg was associated with a significant reduction in HF risk (RR: 0.73, 95%CI: 0.62–0.87). Furthermore, the pooled analysis of prospective randomized controlled trials indicated a significant association between intensive lowering of SBP and HF risk (RR: 0.75, 95%CI: 0.62–0.90) and showed that intensive lowering of SBP could decrease risk of HF in patients without diabetes mellitus (RR: 0.69, 95%CI: 0.52–0.91) and in those ≥65 years old (RR: 0.72, 95%CI: 0.56–0.93), but this finding was not shown for patients with diabetes mellitus (RR: 0.81, 95%CI: 0.56–1.19) or in those <65 years old (RR: 0.81, 95%CI: 0.56–1.19). When intensive lowering of SBP achieved an SBP\u2009≤\u2009120\u2009mmHg, a pooled analysis indicated a positive association between SBP and HF risk (RR: 0.75, 95%CI: 0.63–0.89), and a pooled analyses showed that intensive lowering of SBP could decrease risk of HF in patients without diabetes mellitus (RR: 0.71, 95%CI: 0.51–0.98) and in those ≥65 years old (RR: 0.76, 95%CI: 0.58–0.98); however, this result was not found for patients with diabetes mellitus (RR: 0.81, 95%CI: 0.56–1.19) or those <65 years old (RR: 0.81, 95%CI: 0.56–1.19). The existing data support the results of a positive association between intensive SBP-lowering treatment and HF risk, especially for those patients without diabetes and those older than 65 years. However, additional prospective studies are still needed to confirm these associations.

Volume 33
Pages 648 - 657
DOI 10.1038/s41371-019-0221-z
Language English
Journal Journal of Human Hypertension

Full Text